Immunocompromised patients, such as organ transplant recipients, require careful benefit-risk consideration when selecting a systemic agent for psoriasis. Brodalumab is an immunomodulatory biologic that binds to and inhibits IL-17RA, thereby inhibiting the actions of IL-17A, F, E, and C. Brodalumab has a rapid onset of action, sustained efficacy, and an acceptable safety profile, all of which serve to enhance its appeal as a systemic treatment option for psoriasis in immunocompromised patients. Reports of brodalumab use for psoriasis in organ transplant recipients are limited. We report a case in which brodalumab was used to treat psoriasis in a patient who had undergone solid organ transplantation with excellent response and good tolerability.